Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome
This study is currently recruiting participants.
Verified by National Taiwan University Hospital, March 2005
Sponsored by: National Taiwan University Hospital
Information provided by: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT00167024
  Purpose

Primary: to investigate the effects of DNA repair gene polymorphisms on prostate cancer susceptibility, pathological grade, disease stage and clinical outcome Secondary: to understand the association between DNA repair gene polymorphism and prostate cancer and provided important information for screening, prevention and treatment of prostate cancer


Condition
Prostate Cancer

MedlinePlus related topics: Cancer Prostate Cancer
U.S. FDA Resources
Study Type: Observational
Study Design: Screening, Longitudinal, Defined Population, Retrospective/Prospective Study

Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment: 100
Study Start Date: March 2005
Detailed Description:

DNA repair plays a key role in carcinogenesis through the removal and repair of DNA damage induced by endogenous and environmental sources. The DNA repair system included four pathways: 1) Base Excision Repair (BER), 2) Nucleotide Excision Repair (NER), 3) Mismatch Repair (MMR) and 4) Double-Strand Break Repair, including homologous recombination pathway and nonhomologous end-joining repair pathway. Decreased and impaired DNA repair capacity has been reported in various cancers, however, its effect on prostate cancer still under investigated.

Common polymorphisms in DNA repair gene may alter protein function and individual’s capacity to repair damaged DNA, hence, influence the cancer susceptibility. Polymorphic variants of DNA repair gene have been found to be associated with cancer susceptibility, but rare studies have investigated their effect on prostate cancer. Since variation in the function of these DNA repair genes also impact a cancer cell’s viability or resistance to treatment, genetic variants in DNA repair might serve as a valuable biomarker in forcasting the result of cancer treatment. In fact, some reports have demonstrated the association between polymorphisms of DNA repair genes and results of treatment of various cancers.

For the present study proposal, we focused on several DNA repair genes: X-ray repair cross- complementing group 1 (XRCC1), human oxoguanine glycosylase I (hOGG1), xeroderma pigmentosum complementation group D (XPD), hMSH2, hMLH1 and X-ray repair cross-complementing group 3 (XRCC3), which might have relevance in prostate carcinogenesis based on their known functions. XRCC1 is involved in DNA repair in the base excision pathway, the hOGG1 gene encodes a DNA glycosylase /apurinic-apyrimidinic lyase that catalyzes the excision and removal the 8-OH-dG (8-hydroxy- 2-deoxyguanine) - which is a major form of oxidative DNA damage. The XPD gene codes for a DNA helicase involved in transcription and nucleotide excision repair. The hMSH2 and hMLH1 are genes involved with mismatch repair. The XRCC3 gene encoded a protein in the double-strand break homologous recombinational repair pathways.

In this proposed study, we will also use PCR-based methods to investigate the effects of DNA repair gene polymorphisms on prostate cancer susceptibility, pathological grade, disease stage and clinical outcome. With these efforts, we will further understand the association between DNA repair gene polymorphism and prostate cancer and provided important information for screening, prevention and treatment of prostate cancer.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • prostate cancer approved by pathology

Exclusion Criteria:

  • combined with other malignancy
  • accepting blood transfusion within 6 months
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00167024

Contacts
Contact: Chao-Yuan Huang, MD 886-2-23123456 ext 5238 cyh0909@ha.mc.ntu.edu.tw

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Chao-Yuan Huang, MD     886-2-23123456 ext 5238     cyh0909@ha.mc.ntu.edu.tw    
Principal Investigator: Chao-Yuan Huang, MD            
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Chao-Yuan Huang, MD National Taiwan University Hospital
  More Information

Study ID Numbers: 9461700307
Study First Received: September 12, 2005
Last Updated: November 25, 2005
ClinicalTrials.gov Identifier: NCT00167024  
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
prostate cancer, DNA repair gene, genetic polymorphism

Study placed in the following topic categories:
Prostatic Diseases
Genital Neoplasms, Male
Disease Susceptibility
Urogenital Neoplasms
Genetic Predisposition to Disease
Genital Diseases, Male
Prostatic Neoplasms

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 15, 2009